Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences

RICHMOND, Calif., Sept. 28, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. SGMO announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will participate in the following conferences in October.

• 2017 Cell & Gene Meeting on the Mesa, La Jolla, CA, October 4-6, 2017
  
  Dr. Macrae will participate in a panel discussion on gene editing at 9:15 a.m. PT on Thursday, October 5^th, and is scheduled to present a company overview later that afternoon during the annual Partnering Forum at 2:15 p.m. PT.
  
  
• Jefferies Gene Technology Investor Summit, New York, NY, October 12, 2017
  
  Dr. Macrae is scheduled to present a company overview at 2:50 p.m. ET on Tuesday, October 12^th.

The presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A replay of the presentations will be archived on the Sangamo website for two weeks after the event.

About the Cell & Gene Meeting on the Mesa
Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is the largest partnering meeting organized specifically for the cell and gene therapy sector. This year's meeting will feature more than 70 dedicated company presentations in addition to 90 panelists and featured speakers.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-participation-at-upcoming-investor-and-industry-conferences-300527822.html

SOURCE Sangamo Therapeutics, Inc.